


## Supplementary Figure 1




### Supplementary Figure 1.


PC3 cells were treated with SB203580 (10  $\mu$ M or 50  $\mu$ M), 25  $\mu$ M anisomycin, or the combination for one hour and subjected to western blotting (left). Densitometry analysis of protein bands was performed on Image Studio to calculate fold change of p-Hsp27 (Ser82) relative to tubulin (right). Bars represent the mean of three independent experiments  $\pm$  S.E.M (\*:  $p \leq 0.05$ ).

## Supplementary Figure 2

(a)



(b)



### Supplementary Figure 2.

(a) Subcutaneous V16D xenografts were established and treatment with vehicle or SB203580 (10 mg/kg) started when tumors reached 200 mm<sup>3</sup> (Day 0), in a 5 days on and 2 days off schedule until endpoint. Tumor growth curves from individual mice are shown normalized to their starting volume. (b) PSA was measured by ELISA in blood samples from tumor-bearing mice. Fold change in PSA for each mouse in their last week of life is plotted for each treatment group. A Mann-Whitney test was used to obtain the displayed p-value.

## Supplementary Table 1

	Vehicle (n=10)	SB203580 (n=10)
Average tumor volume at Day 0 [mm <sup>3</sup> ]	216.0	202.9
Standard Deviation of tumor volumes at Day 0 [mm <sup>3</sup> ]	39.3	26.6
Median tumor volume at Day 0 [mm <sup>3</sup> ]	200.6	191.3
Interquartile range of tumor volumes at Day 0 [mm <sup>3</sup> ]	38.7	43.0
Median number of days to endpoint	28.0	40.5
Interquartile range of days to endpoint	12.0	21.5

### Supplementary Table 1.

Tumor volume and endpoint characteristics for treatment groups.